Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.47 USD

74.47
1,666,282

+0.69 (0.94%)

Updated Aug 19, 2024 03:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead's CAR-T Therapy Yescarta Gets Approval in Europe

Gilead's (GILD) CAR-T therapy, Yescarta gets approval in Europe for adult patients suffering from relapsed or refractory DLBCL and PMBCL, after two or more lines of systemic therapy.

    Zacks.com headshot

    Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris

    Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.

      Novartis' CAR-T Therapy Kymriah Gets Approval in Europe

      Novartis (NVS) gets EC approval for CAR-T therapy, Kymriah, for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia.

        Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events

        Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

          Why Is Gilead (GILD) Down 6.2% Since Last Earnings Report?

          Gilead (GILD) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.

            Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema

            Shire???s (SHPG) Takhzyro gets approval from the FDA for the treatment of hereditary angioedema in patients 12 years of age and older. It is the first-of-its-kind mAb preventive treatment for the same.

              Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test

              Roche's (RHHBY) cobas EGFR Mutation Test v2 gets FDA nod as a companion diagnostic test with IRESSA.

                AbbVie Posts Positive Data on Elagolix for Uterine Fibroids

                AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.

                  Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer

                  Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.

                    Ekta Bagri headshot

                    4 Biotech Stocks Investors Can Bet on Post Solid Q2 Earnings

                    The biotech sector is expected to do well in the second half of 2018. Here we list four top biotech companies, which investors can add to their portfolio.

                      Mallinckrodt's Stannsoporfin Gets Complete Response Letter

                      Mallinckrodt's (MNK) pipeline candidate, Stannsoporfin gets a Complete Response Letter from the FDA.

                        John Blank headshot

                        Don't Worry About An Inverted Yield Curve...YET

                        The U.S. economy should remain out of recession until 2020.

                          Alnylam Completes Enrollment in Phase III Givosiran Study

                          Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.

                            Pacira (PCRX) Rides High on Robust Exparel Performance

                            Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.

                              Allergan Falls on FDA's Rejection of Uterine Fibroids Drug

                              FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.

                                Infinity Focuses on Developing IPI-549 for Solid Tumors

                                Infinity Pharmaceuticals (INFI) aims at developing its pipeline candidate, IPI-549.

                                  Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC

                                  AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.

                                    Alexion's BLA for ALXN1210 Gets Priority Review From FDA

                                    The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.

                                      China Biologic Products (CBPO) Looks Good: Stock Adds 8.7% in Session

                                      China Biologic Products (CBPO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

                                        The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor

                                        The Zacks Analyst Blog Highlights: Amazon, Petroleo Brazileiro, Gilead Sciences and KLA-Tencor

                                          Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer

                                          Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.

                                            Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

                                            Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.

                                              John Blank headshot

                                              Time for Jackson Hole: Global Week Ahead

                                              The world???s central bankers are going to be in Jackson Hole, Wyoming speaking to Jerome Powell and the rest of the Fed contingent. Mr. Powell himself will speak Friday morning.

                                                Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

                                                Is (GILD) Outperforming Other Medical Stocks This Year?

                                                  Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

                                                  Is (GILD) Outperforming Other Medical Stocks This Year?